Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy.
Assessment of Helicobacter pylori antigen in stool specimens has recently been proposed as a valid method for the noninvasive detection of H. pylori infection, especially as posttreatment control. After the development of an enzyme immunoassay based on polyclonal antibodies (Premier Platinum HpSA) a monoclonally based test has recently been developed (FemtoLab H. pylori). The aim of the present study was to assess the diagnostic accuracy of both tests in adult patients undergoing H. pylori eradication therapy. Stool samples were collected and the 13C-urea breath test performed in 148 patients (79 females and 69 males aged 21-75 yr) 4-6 wk after eradication therapy. The FemtoLab H. pylori and Premier Platinum HpSA tests were performed in accordance with the manufacturers' protocols. A receiver operator characteristics analysis was performed to define the optimal cutoff value on the basis of the results of the 13C-urea breath test. H. pylori eradication was successful in 113 of the 148 patients (76%). After adjusting the cutoff, the sensitivity of FemtoLab H. pylori was found to be higher than that of the Premier Platinum HpSA (94.3% vs 80.0%, ns). Specificity, positive predictive value, and negative predictive value of the two tests were comparable (93.8% vs 95.6%, 82.8% vs 85.2%, and 98.1% vs 93.8%, respectively). The new stool antigen test (FemtoLab H. pylori) is an excellent tool for diagnosing H. pylori infection after eradication therapy, and its accuracy is comparable with that of the Premier Platinum HpSA. Adjustment of the cutoff after H. pylori eradication therapy increases the overall accuracy.